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Abstract
Background: Drug-resistance mutations (DRAM) are frequently selected in patients with virological failure defined as viral
load (pVL) above 500 copies/ml (c/mL), but few resistance data are available at low-level viremia (LLV). Our objective was to
determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral
therapy (ART).
Methods: Retrospective analysis of patients presenting a LLV episode defined as pVL between 40 and 500 c/mL on at least 3
occasions during a 6-month period or longer while on the same ART. Resistance genotypic testing was performed at the
onset and at the end of LLV period. Emerging DRAM was defined during LLV if never detected on baseline genotype or
before.
Results: 48 patients including 4 naive and 44 pretreated (median 9 years) presented a LLV episode with a median duration
of 11 months. Current ART included 2NRTI (94%), ritonavir-boosted PI (94%), NNRTI (23%), and/or raltegravir (19%). Median
pVL during LLV was 134 c/mL. Successful resistance testing at both onset and end of the LLV episode were obtained for 37
patients (77%), among who 11 (30%) acquired at least 1 DRAM during the LLV period: for NRTI in 6, for NNRTI in 1, for PI in 4,
and for raltegravir in 2. During the LLV period, number of drugs with genotypic resistance increased from a median of 4.5 to
6 drugs. Duration and pVL level of LLV episode, duration of previous ART, current and nadir CD4 count, number of baseline
DRAM and GSS were not identified as predictive factors of resistance acquisition during LLV, probably due to limited
number of patients.
Conclusion: Persistent LLV episodes below 500 c/ml while receiving ART is associated with emerging DRAM for all drug
classes and a decreasing in further therapeutic options, suggesting to earlier consider resistance monitoring and ART
optimization in this setting.
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Introduction
HIV drug resistance is related to the selection of viral variants
harbouring drug resistance associated mutations (DRAM) in the
target genes of antiretroviral drugs, promoted by ongoing viral
replication in patients receiving antiretroviral therapy (ART).
Cross-sectional studies showed that DRAMs occurred in 88% of
HIV-infected patients on ART when virological failure (VF),
defined as a plasma viral load (pVL) above 1000 copies/mL (c/
mL) [1]. Moreover, accumulation of DRAMs increases when
maintaining a failing drug regimen with pVL above 400 c/mL
[2,3], leading to a loss of future therapeutic options also due to a
large cross-resistance between drug within each antiretroviral
class. These data support the current guidelines which recommend
a rapid therapeutic switch for a new potent regimen when VF is
detected, including at least two fully active drugs.
In recent years, the improvement of assays to quantify pVL led
to progressively decrease the threshold of VF. In French
recommendations, VF was defined as two consecutive plasma
HIV-1 RNA quantifications above 1000 copies/ml in 2004 [4],
then above 500 copies/ml in 2006 [5]. Since 2008, VF is defined
as a confirmed pVL above 50 c/mL in French and European
guidelines [6,7]. In addition, because of the current availability of
several antiretroviral drugs targeting different steps of viral cycle, a
larger proportion of HIV-infected patients are now receiving ART
and most of them are virologically suppressed [8,9,10]. However
some of them experienced persistent low level viremia (LLV)
episodes, defined as repeated pVL between 50 and 500 or 1000 c/
mL, under stable ART which, unlike intermittent viremia or blip.
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activation [11], increased risk of virologic failure [11,12], and
perhaps increased mortality [13].
Although accumulation of DRAM is well known for pVL above
400 c/mL, the diagnosis and the management of emerging drug
resistance during LLV remain a clinical challenge since standard
genotypic tests fail to amplify HIV-1 RNA below 500 c/mL in
45% [14] and conventional genotyping is recommended for pVL
above 1,000 c/mL [15]. Hence without data of resistance
genotyping test, during LLV, clinicians can either switch by
excess to a new suppressive therapy when the virus is still sensitive
or in contrary maintain the regimen when DRAM have already
emerged and still accumulate.
To longitudinally detect the development of DRAM during
LLV, we retrospectively analyzed HIV-1-infected patients fol-
lowed in two French hospital clinical cohorts. We aim to describe
the clinical and virological characteristics of those patients
experiencing LLV, and to analyze the dynamics of emergence of
genotypic drug-resistance in this setting.
Methods
Ethics statements
This study was a non-interventional study with no addition to
usual procedures. Biological material and clinical data were
obtained only for standard viral diagnostic following physicians’
prescriptions (no specific sampling, no modification of the
sampling protocol, no supplementary question in the national
standardized questionnaire). Data analyses were carried out using
an anonymized database. The protocol was approved by the local
ethical research committee (Persons Protection Committee Ile-de-
France XI, nu11062, july 2011), which confirmed exemption from
patient informed consent, according to the French Public Health
Law CSP Art. L 1121-1.1.
Selection of patients
Subjects were retrospectively identified from a routine virolog-
ical monitoring database from two French Infectious Diseases
clinics. LLV cases were defined as subjects who experienced pVL
between 50 and 500 c/mL on at least 3 occasions during a 6-
month period or longer while on the same ART regimen. During
the LLV period, no more than 3 pVL below 50 c/mL were
allowed.
The onset of LLV period was different according to the pVL at
the beginning of the current treatment. In naı ¨ve patients and in
patients failing previous treatment, the onset of LLV period was
defined as the first date of pVL between 50–500 c/mL during the
follow-up after having received at least 6 months of the same ART
regimen. In patients virologically suppressed, the onset of LLV
period was defined as the date of the first pVL between 50–500 c/
mL. The LLV period ended at the last low-level viral load
measurement between 50–500 c/mL and before VF (defined as a
confirmed pVL above 500 c/mL or a single pVL above 1000 c/
mL), or before ART modification decided by the physician.
Genotype analysis
To analyze the emergence of DRAM, resistance genotyping
tests (RGT) were performed from several plasma time-points of the
LLV period. The first RGT (G1) was performed at the beginning
of the ART regimen under which LLV was detected, or at the
onset of the LLV period. A second RGT (G2) was performed at
the end of the LLV period or if the PCR amplification failed, from
prior available samples with detectable viremia during the LLV
period.
RNA was extracted from 1 to 1.5 ml of frozen plasma using the
QIAamp viral RNA minikit (Qiagen, Courtaboeuf, France) after a
2 hours-ultracentrifugation at 28 000XG at 4uC to pellet virus
particles. Regions of the pol gene containing protease, reverse
transcriptase (RT) and integrase (for patients receiving raltegravir-
containing regimen) genes were amplified by RT-PCR followed by
nested PCR (www.hivfrenchresistance.org).
Population sequencing was performed on purified amplicons
(ExoSap-IT Purification Kit, Abbott, Rungis, France) with the
Taq Dye Deoxy Terminator cycle sequencing kits (Applied
Biosytems, France) and resolved on an ABI 3730 automated
DNA sequencer. Sequences were processed using SmartGeneH
HIV-1 Sequence Analysis and Database Module (SmartGene
GmbH, Zug, Switzerland) and aligned to the HIV-1 subtype B
reference strain HXB2 (GenBank accession no. K03455).
Drug-resistance mutations were identified according to the 2009
International AIDS Society (IAS)-USA list (www.iasusa.org) and
drug susceptibility was assessed using the 2009 ANRS HIV-1
drug-resistance algorithm v18 (www.hivfrenchresistance.org). Ge-
notypic susceptibility score (GSS) to the current regimen was
calculated as the sum of active (=1), partially active (=0.5) and
inactive (=0) drugs. Mixtures of a mutated and wild-type HXB2
strain were counted as mutations. Mutations present at G1 were
assumed to be still present at G2 as it has been shown that once a
mutation has been accumulated, it persists in minority viruses even
if it is not detected by population sequencing [16]. All DRAM
selected during LLV period was considered as new one if never
described in G1 or in any available RGT performed previously to
the study.
Patients in whom RT or protease amplification failed were
excluded from the resistance analysis.
Statistical analysis
Descriptive statistics are given as median and Inter Quartil
Range (IQR) for continuous variables and percent for categorical
variables. A logistic regression model was used to investigate
whether the following variables were associated with an increase
risk of the emergence of a new DRAM: ART type, treatment
duration, nadir and current CD4 cell count baseline pVL, number
of DRAM at G1, GSS, duration of LLV period, level of pVL
during LLV and number of LLV episodes above 50 c/mL.
Results
Baseline characteristics of patients
We included in the study 48 HIV-1-infected patients with an
identified episode of LLV (Table 1). Patients were male (71%),
with a median age of 44 years. They were HIV-1-infected since a
median of 12 years. Patients had a median nadir CD4 cell count of
65 cells/mL and 28 patients (58%) were classified as CDC stage
C. Four patients were receiving a first ART regimen and 44 were
already ART-treated since a median time of 9 years. Those
pretreated patients have received before the study a median
number of nucleoside reverse transcriptase inhibitors (NRTI) of
five, of non-nucleoside reverse transcriptase inhibitors (NNRTI) of
one and of protease inhibitors (PI) of two.
The median of pVL and CD4 cell count at the initiation of the
current ART were 3.7 (Inter Quartil Range, 2.1 to 4.7) log10 c/
mL and 255 (98 to 430) cells/mL, respectively. Current ART
included at least 2 NRTI in 45 patients (94%): lamivudine (3TC)
or emtricitabine (FTC) in 43 patients (90%), tenofovir (TDF) in
27 patients (56%) and abacavir (ABC) in 13 patients (27%). Forty
five patients (94%) received ritonavir boosted-PI (PI/r): lopinavir
(LPV) in 13 patients (29%) and darunavir (DRV) in 15 patients
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raltegravir (RAL) based-regimen, respectively.
Description of the LLV period
The median duration of the LLV period was 11 (9 to 16)
months. During the LLV period, the median higher pVL was 222
(150 to 341) c/mL and the median of the average pVL was 134
(104 to 194) c/mL. The median number of pVL measurements
above 50 c/mL was 4 (3 to 6). A single pVL above 500 c/mL was
observed in 4 (8%) patients. The median CD4 cells count at entry
in the LLV period was 371 [238 to 548] and the end of the LLV
period the median was 415 [243 to 576].
HIV drug resistance mutations before LLV period
For the 48 patients, we generated a total of 96 RT and PR
sequences from the samples corresponding to G1 and G2,
including 72 plasmas with low-level of replication (median
133 c/mL) for which the rate of successful amplification was
71% (51/72). For the 9 patients receiving a RAL-containing
regimen, we successfully amplified the integrase gene in 9 from the
13 (75%) plasmas analyzed (median 213 c/mL). Overall, success-
ful resistance genotypic tests for both G1 and G2 were obtained in
37 patients among 48 (77%) (Figure 1): three were receiving a first
ART and 34 were already pretreated with at least one previous
experience of VF. Among the 34 pretreated patients, the
prevalence of drug resistance at the onset of LLV was assessed
using only one RGT (G1) for 12 (35%) patients, two RGT (G1 and
one previous test) for 8 (24%) and 3 or more RGT for 14 (41%).
The median (IQR) numbers of DRAM in G1 for each
antiretroviral drug class were 3 (0 to 5) for NRTI, 1 (0 to 2) for
NNRTI, 1 (0 to 4) for PI (major mutations) (Figure 1). The most
frequent DRAM ($20%) were found in the RT gene at codons 41
(32%), 67 (30%), 74 (22%), 184 (59%), 210 (22%), 215 (32%) and
103 (22%), and in the protease gene (major mutations) at codons
46 (38%), 54 (35%), 82 (32%), 84 (24%) and 90 (24%) (Figure 1).
No DRAM was detected in the integrase gene before receiving
RAL.
According to the 2009 ANRS HIV-1 drug-resistance algorithm
v18, DRAM present in G1 or in previous RGT conferred
resistance to a median (IQR) of 4.5 (1–11.9) antiretroviral drugs: 1
(0–4.4) for NRTI, 0 (0–2) for NNRTI and 1.75 (0.5–6) for PI
(Figure 2). The median (IQR) GSS to the current ART was 3 (2–
3).
Acquisition of resistance mutations during LLV
Overall, 11 patients among 37, (30%), all pretreated, acquired
at least one new DRAM (median 2, ranging from 1 to 9) over the
study period (Table 2, Figure 1). New resistance mutations were
observed for NRTI in 6 patients (16%), for NNRTI in 1 patient
(2.7%), for PI (major mutations) in 4 patients (11%) and for RAL
in 2 patients (5.4%). According to the current regimen, 3 patients
from the 33 who received 3TC or FTC acquired M184V mutation
(9%), one patient from the 8 who received NNRTI acquired
K103N mutation (12.5 %), 4 patients from the 32 who received PI
acquired major PI mutations (12.5 %) and 2 patients from the 7
who received RAL acquired IN mutations (29%).
During the LLV period, the median number of drugs with
genotypic resistance increased from 4.5 at G1 to 6 (1.1–11.9) at G2
(Figure 2). The sensitivity analysis to antiretroviral drugs before
and after the LLV period showed an increased resistance for 12 of
the 18 studied drugs. The median (IQR) GSS to the current
treatment remained 3 (2–4).
We investigated if some virological or therapeutic factors were
predictive to the emergence of new DRAM during LLV. Among
ART type, treatment duration, nadir and current CD4 cell count,
baseline pVL, number of DRAM at G1, GSS, duration of LLV
period, level of pVL during LLV and number of LLV episodes
above 50 c/mL, no factors was significantly associated with the
emergence of new DRAM (data not shown).
Discussion
We retrospectively analyzed 48 patients from two hospital
cohorts presenting LLV episodes defined by at least three pVL
between 50 and 500 c/mL after 6 months of ART regardless of
treatment lines and regimen. All these patients were followed in
‘‘real-life’’ conditions and were heterogeneous for ART history, for
prior treatment failure and for presence of drug-resistant viruses.
When comparing RGT before and at end of the LLV period, we
found that new DRAM occurred in 30% of evaluable cases during
LLV and according to the regimen, new mutations conferring
resistance to NRTI, NNRTI, PI and raltegravir were observed in
14%, 12.5%, 12.5% and 29% of patients, respectively.
Detection, but not selection, of DRAM for pVL below 500 c/
mL under ART, is frequent in transversal cohorts [14,17] and a
recent analysis using a simulation technique, showed that the risk
for emerging resistance was estimated to occur in 65% during
detectable VL, excluding blips, below 500 c/mL [17]. Our
longitudinal analysis of genotypic drug resistance evolution during
LLV showed that selection of DRAM could occur, even at low
levels of viral replication (#200 c/mL) and in patients receiving a
PI/r containing regimen.
Ritonavir boosted PI-based regimen are at lower risk of
selection of DRAM both in the RT and in the protease genes
[18,19]. We reported here the selection of new major DRAM in
the protease gene in 4 patients receiving a boosted PI-based
regimen (12.5%), when emerging PI resistance was rarely
described during LLV [20]. In addition, we detected selection of
TAM in also 3 patients. Duration of the LLV period of our study
was long (median 11 months, up to 43 months), which could have
contributed to the emergence of resistance to higher genetic
Table 1. Baseline characteristics of 48 patients experiencing
low-level viremia episodes.
Total N=48
Age (years) Median (IQR) 44 (40–51)
Sex Males, n (%) 34 (71%)
Time since HIV diagnosis (years) Median (IQR) 12 (7–18)
CDC classification Status C, n (%) 28 (58%)
Nadir CD4 (cells/ml) Median (IQR) 65 (11–217)
HIV-1 subtype Subtype B, n (%) 25 (52 %)
Duration of ART at baseline (years) Median (IQR) 8 (4–10)
Previous antiretroviral drugs NRTI, n (%) 5 (0–7)
NNRTI, n (%) 1 (0–3)
PI, n (%) 2 (0–7)
Patients with previous virological
failure
n (%) 44 (92%)
CD4 at the onset of current ART Median (IQR) 255 (98–430)
pVL at the onset of current ART Median (IQR) 3.7 (2.1–4.7)
ART: antiretroviral therapy, NRTI: nucleoside reverse transcriptase inhibitors,
NNRTI: non-nucleoside reverse transcriptase inhibitors, PI: protease inhibitors.
doi:10.1371/journal.pone.0036673.t001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36673Figure 1. Resistance-associated mutations to nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse
transcriptase inhibitors (NNRTI), protease inhibitors (PI) and integrase inhibitors (INI) before and after the low-level viremia
(LLV) period, according to the 2009 International AIDS Society-USA list.
doi:10.1371/journal.pone.0036673.g001
Figure 2. Resistance to antiretroviral drugs at the onset and the end of the low-level viremia period, assessed using the 2009 ANRS
HIV-1 drug-resistance algorithm v18. LLV: low level viremia, 3TC/FTC: lamivudine/emtricitabine, ZDV: zidovudine, d4T: stavudine, ABC: abacavir,
ddI: didanosine, TDF: tenofovir, EFV: efavirenz, NVP: nevirapine, ETV: etravirine, IDV: indinavir, NFV: nelfinavir, TPV: tipranavir, SQV: saquinavir, LPV:
lopinavir, ATV: atazanavir, FPV: fosamprenavir, DRV: darunavir, RAL: raltegravir.
doi:10.1371/journal.pone.0036673.g002
Drug-Resistance during Low-Level Viremia
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We can not however exclude that these resistance mutations had
been selected during previous VF, still present at minority level
and/or archived in cellular reservoir and re-emerged upon a
modification of antiretroviral pressure. Indeed, the selection of
additional DRAM in our study, was observed only in pre-treated
patients.
Emerging resistance to low-genetic barrier drug was detected in
three patients for 3TC/FTC (9%) and in one for EFV (12.5%).
Selection of DRAM during LLV was previously reported in 67%
of naı ¨ve and pretreated patients receiving 3TC and EFV based-
regimen [21], when in this study the median pVL during LLV was
higher (417 c/mL). Furthermore in a sub analysis of two large
trials in patients receiving an initial NRTI with EFV or LPV/r, or
EFV and LPV/r containing ART, new DRAM were selected
during LLV (median pVL of 77 c/mL) in 37% patients mainly at
codons 184 and 103 of the RT gene but not in the PR gene [22].
In addition, new raltegravir-associated DRAM were detected in
2 of the 7 (29%) patients who were receiving raltegravir. Selection
of DRAM in the integrase gene was previously reported in 8% of
39 highly-pretreated patients receiving a raltegravir and boosted-
PI containing regimen, who experienced at least one episode of
detectable viremia below 500 c/mL [23], but not confirmed
elsewhere [24,25]. Emerging resistance to raltegravir, otherwise
considered to be a low-genetic barrier drug, seems to rarely occur
during LLV in pretreated patients, suggesting a reduced fitness of
highly mutated resistant viruses.
Finally, higher level of pVL and non-Hispanic black ethnicity
were previously associated with the risk of emerging resistance in
patients receiving an initial ART and presenting LLV [22]. Here
we failed to identify risk factors associated to the acquisition of new
DRAM, probably because of an unpowered sample size of patients
retrospectively analyzed.
In conclusion, our study lead in standard clinical practice,
confirms that new DRAM during LLV can emerge, regardless of
the ARV antiretroviral target genes, and can remarkably reduce
the current therapeutic options for further regimen. Both French
and American 2010 antiretroviral guidelines recommend a rapid
therapeutic intervention when VF if pVL is over 200 c/mL [6,15],
but a simple monitoring of pVL, drug-resistance and CD4 cell
count evolution if pVL is below 200 c/mL. Our data underline
here that persistent LLV is not a neutral virological circumstance
in term of emergence of drug resistance, and for which RGT has a
potential interest, in order to help to an early therapeutic
optimization, whose efficacy still needs to be assessed in the future.
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